Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain) A single dose of KSI-101 resulted in the majority of patients achieving resolution of intra-retinal and sub-retinal fluid and over 90% of patients achieved retinal dryness by Week 8 The Phase 3 PEAK and PINNACLE studies of KSI-101 are actively... Read More

PALO ALTO, Calif. , Sept. 2, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced participation in two upcoming scientific meetings: The 25 th EURetina Congress and The Retina Society 58 th Annual Scientific Meeting. At both conferences, Charles Wykoff , MD, PhD, will... Read More

PALO ALTO, Calif. , Aug. 19, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present the Company's pipeline programs in glaucoma at the American Chemical Society (ACS) Fall 2025 Meeting on Tuesday, August 19, 2025 , in Washington, D.C.... Read More

PALO ALTO, Calif. , Aug. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025 . "Our July 16 Investor R&D Day brought forward compelling new data along with a clear commercial vision for our three late-stage clinical assets –tarcocimab, KSI-501 and KSI-101– underscoring their transformative potential in retinal... Read More

PALO ALTO, Calif. , July 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics, announced today it will host an investor R&D Day webcast on Wednesday, July 16, 2025 , from 4:00 pm ET to 5:30 pm ET . The virtual event will feature a comprehensive overview of Kodiak's three... Read More

PALO ALTO, Calif. , June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management along with key opinion leaders will present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS) in Rio de... Read More

PALO ALTO, Calif. , May 29, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth , M.D., Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City , NY on Thursday, June 5, 2025 ,... Read More

PALO ALTO, Calif. , May 14, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025. "In the first quarter of 2025, we maintained a strong focus on execution. We look forward to sharing our progress at an Investor R&D Update scheduled for July 16, 2025 at 1:00pm Eastern Time . We aim to demonstrate that our vision for... Read More

PALO ALTO, Calif. , May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that seven scientific presentations on its research programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, being held... Read More

PALO ALTO, Calif. , March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024 . "In September of 2024 we hosted an Investor R&D Day in New York ," said Victor Perlroth , M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation featured scientific,... Read More

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance PALO ALTO, Calif. , March 10, 2025 /PRNewswire/ - - Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in... Read More

PALO ALTO, Calif. , Feb. 4, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February... Read More

PALO ALTO, Calif. , Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth , M.D., Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15,... Read More

PALO ALTO, Calif. , Nov. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024 . "In the third quarter we hosted an Investor R&D Day in New York ," said Victor Perlroth , M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation provide a comprehensive and up-to-date overview of... Read More

PALO ALTO, Calif. , Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences. Members of the management team will also be available for one-on-one meetings. Jefferies... Read More

PALO ALTO, Calif. , Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024 , in Chicago, Illinois . Presentation and Panel details are below:... Read More

NEW YORK , Sept. 23, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), will host its Investor R&D Day today in New York . The event is from 10:30 am ET to 12:30 pm ET and can be accessed virtually by clicking here . A link to the live webcast, replay and presentation slides of the event will be available on the "Events and Presentations" section of Kodiak's Investors & Media website at http://ir.kodiak.com/ . A replay... Read More

PALO ALTO, Calif. , Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024 , in New York City from 10:30 am ET to 12:30... Read More

PALO ALTO, Calif. , Aug. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024 . "Our three clinical programs of tarcocimab, KSI-501 and KSI-101 are making strong operational progress," said Victor Perlroth , M.D., Chief Executive Officer of Kodiak Sciences. "The Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy... Read More

PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences: Jefferies Healthcare Conference, June 6, 2024 , 8:00 AM ET ( 5:00 AM PT ), New York, New... Read More

PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue to make excellent operational progress with our three clinical programs of tarcocimab, KSI-501 and KSI-101, as well as on our duet and triplet research programs," said Victor Perlroth , M.D., Chief Executive Officer of Kodiak Sciences.... Read More

PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer. GLOW2 is the... Read More

Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile. KSI-501 clinical and non-clinical data highlight multiple ascending dose safety, bioactivity and durability in treatment-naïve and treatment-experienced patients and next steps of Phase 3 development for KSI-501 and Phase 1b development for KSI-101. Novel small molecules... Read More

Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively recruiting Phase 1b study of KSI-101 planned for 2Q2024 with the goal of initiating dual pivotal studies in 2024 New Phase 3 DAYBREAK study in wet AMD to include KSI-501 and tarcocimab... Read More

PALO ALTO, Calif. , March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024 . Management will host a conference call and live webcast to discuss... Read More

PALO ALTO, Calif. , Jan. 30, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that first time results of the KSI-501ABC Phase 1 Study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting. KSI-501ABC is the second... Read More

PALO ALTO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 , at 7:30 a.m. Pacific Time ( 10:30... Read More

PALO ALTO, Calif. , Nov. 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 6 th Annual Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023 , at 3:25 p.m. Eastern Time ( 12:25... Read More

PALO ALTO, Calif. , Nov. 14, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023 . "We have three retinal disease prospects in our pipeline: two molecules built with our antibody biopolymer conjugate platform (ABC Platform), (1) tarcocimab ABC, an anti-VEGF bioconjugate, (2) KSI-501 ABC, a bispecific anti-IL-6 and anti-VEGF... Read More

Primary endpoint and all key secondary endpoints met with high statistical significance in GLOW study. With 6-month dosing of all patients, tarcocimab and the ABC platform continue to demonstrate differentiated durability. Following dialogue with US regulatory authorities, Kodiak plans to conduct one additional pivotal study with a commercial formulation of tarcocimab. New regulatory strategy could support a single Biologics... Read More

PALO ALTO, Calif. , Nov. 1, 2023 /PRNewswire/ -- Kodiak Sciences Inc (NASDAQ: KOD) today announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 3-6 in San Francisco . During the Retina Subspecialty Day on November 3 , detailed results will be presented for the first time from the Phase 3 GLOW study of tarcocimab tedromer in... Read More

PALO ALTO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that three scientific presentations on tarcocimab tedromer (KSI-301), including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet... Read More

PALO ALTO, Calif. , Sept. 8, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Morgan Stanley 21 st Annual Global Healthcare Conference in New York, NY on Wednesday, September 13, 2023 , at 12:55 p.m. Eastern Time... Read More

Tarcocimab demonstrated strong durability, matched efficacy and comparable safety versus aflibercept in a head-to-head comparative pivotal trial over one-year After 4 initiating doses in the first 6 months, approximately half of tarcocimab-treated patients required no additional injections in the second 6 months Low and comparable rates of cataract adverse events were observed (tarcocimab 4.9% vs aflibercept 2.8%) These... Read More

PALO ALTO, Calif. , Aug. 14, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended June 30, 2023 . "We experienced a significant setback with the recently announced topline data for our... Read More

PALO ALTO, Calif. , July 24, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD) announced today topline results from three Phase 3 studies of tarcocimab tedromer, a novel antibody biopolymer conjugate. The DAYLIGHT study was a randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of a high intensity dosing regimen of tarcocimab tedromer in 557 treatment-naïve subjects with wet... Read More

PALO ALTO, Calif. , May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences: Jefferies Healthcare Conference, June 7, 2023 , 1:30 PM ET ( 10:30 AM PT ), New York, New York... Read More

PALO ALTO, Calif. , May 15, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended March 31, 2023 . "We are on the cusp of four Phase 3 study readouts in major indications, starting with... Read More

PALO ALTO, Calif. , April 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc . (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that multiple scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology (ARVO)... Read More

PALO ALTO, Calif. , April 3, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that the first patient has been treated in the Phase 1 study of KSI-501, an investigational bispecific antibody biopolymer conjugate targeting both VEGF and IL-6. KSI-501... Read More

PALO ALTO, Calif. , March 28, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2022 . "We are running a comprehensive development program for tarcocimab tedromer... Read More

PALO ALTO, Calif. , Feb. 9, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that a presentation will be made at the upcoming Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting including clinical data from Kodiak's investigational... Read More

PALO ALTO, Calif. , Jan. 4, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023 , at 9:00 a.m. Pacific Time ( 12:00... Read More